Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Children's Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00003846 |
RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of radiation therapy and chemotherapy and kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of radiation therapy, chemotherapy and peripheral stem cell transplantation in treating patients with primitive neuroectodermal tumors.
Condition | Intervention | Phase |
---|---|---|
Brain and Central Nervous System Tumors Neuroblastoma |
Drug: carboplatin Drug: cyclophosphamide Drug: filgrastim Drug: thiotepa Drug: vincristine sulfate Procedure: bone marrow ablation with stem cell support Procedure: peripheral blood stem cell transplantation Procedure: radiation therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support |
Estimated Enrollment: | 56 |
Study Start Date: | July 1999 |
OBJECTIVES:
OUTLINE: This is a dose-escalation study of thiotepa during consolidation therapy.
For consolidation therapy, cohorts of 6-12 patients each receive escalating doses of thiotepa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 12 patients experience dose-limiting toxicity.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 24-56 patients will be accrued for this study.
Ages Eligible for Study: | 3 Years to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically proven primitive neuroectodermal tumor (PNET) of one of the following types:
Nonposterior fossa PNET and other types must be M0-3
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Pulmonary:
FEV_1/FVC greater than 60% except for children who:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, California | |
Children's Hospital Los Angeles | |
Los Angeles, California, United States, 90027-0700 | |
Children's Hospital of Orange County | |
Orange, California, United States, 92668 | |
Jonsson Comprehensive Cancer Center, UCLA | |
Los Angeles, California, United States, 90095-1781 | |
United States, Colorado | |
Children's Hospital of Denver | |
Denver, Colorado, United States, 80218 | |
United States, District of Columbia | |
Children's National Medical Center | |
Washington, District of Columbia, United States, 20010-2970 | |
United States, Minnesota | |
University of Minnesota Cancer Center | |
Minneapolis, Minnesota, United States, 55455 | |
United States, New York | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10021 | |
NYU School of Medicine's Kaplan Comprehensive Cancer Center | |
New York, New York, United States, 10016 | |
United States, Ohio | |
Children's Hospital Medical Center - Cincinnati | |
Cincinnati, Ohio, United States, 45229-3039 | |
Children's Hospital of Columbus | |
Columbus, Ohio, United States, 43205-2696 | |
United States, Oregon | |
Oregon Cancer Center at Oregon Health Sciences University | |
Portland, Oregon, United States, 97201-3098 | |
United States, Texas | |
University of Texas - MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
United States, Washington | |
Fred Hutchinson Cancer Research Center | |
Seattle, Washington, United States, 98109 |
Study Chair: | H. Stacy Nicholson, MD, MPH | Oregon Health and Science University Cancer Institute |
Study ID Numbers: | CDR0000067006, COG-99702, CCG-99702 |
Study First Received: | November 1, 1999 |
Last Updated: | August 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00003846 |
Health Authority: | United States: Federal Government |
regional neuroblastoma disseminated neuroblastoma stage 4S neuroblastoma |
untreated childhood supratentorial primitive neuroectodermal tumor untreated childhood medulloblastoma newly diagnosed childhood ependymoma |
Neuroectodermal Tumors, Primitive Vincristine Carboplatin Central Nervous System Neoplasms Cyclophosphamide Neuroblastoma Ependymoma Thiotepa |
Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Medulloblastoma Neuroepithelioma Nervous System Neoplasms Neuroectodermal Tumors, Primitive, Peripheral Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Mitosis Modulators Nervous System Diseases Neoplasms, Nerve Tissue Physiological Effects of Drugs Antimitotic Agents Immunosuppressive Agents Pharmacologic Actions |
Neoplasms Neoplasms by Site Therapeutic Uses Tubulin Modulators Myeloablative Agonists Antineoplastic Agents, Alkylating Neoplasms, Neuroepithelial Antirheumatic Agents Antineoplastic Agents, Phytogenic Alkylating Agents |